Diagnostic and prognostic markers in gliomas

Area of Science:

• Neuro-oncology
• Molecular Pathology
• Genetics

Background:

• Gliomas are primary brain tumors with diverse molecular profiles.
• Accurate classification relies on identifying specific diagnostic and prognostic markers.
• Advancements in molecular biology have revealed new markers for glioma subtyping.

Purpose of the Study:

• To review recent studies on diagnostic and prognostic markers in gliomas.
• To highlight key molecular alterations such as BRAF fusions, 1p/19q codeletion, MGMT status, and IDH mutations.
• To discuss the impact of these markers on glioma classification and patient management.

Main Methods:

• Literature review of recent studies on glioma molecular markers.
• Analysis of diagnostic and prognostic significance of identified genetic alterations.
• Synthesis of findings related to BRAF fusions, 1p/19q codeletion, MGMT, and IDH mutations.

Main Results:

• BRAF fusion gene identified as a specific and frequent marker in pilocytic astrocytomas, targeting the MAPK pathway.
• 1p/19q codeletion and O-6-methylguanine-DNA methyltransferase (MGMT) status remain crucial prognostic and predictive markers in diffuse gliomas and glioblastomas.
• Isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are specific to diffuse gliomas, offering prognostic value in grade III gliomas and identifying secondary glioblastomas.

Conclusions:

• Molecular studies have led to the discovery of novel diagnostic and prognostic markers for gliomas.
• These markers are crucial for refining the histomolecular classification of gliomas.
• Continued research into molecular markers promises improved glioma diagnosis, prognosis, and targeted therapies.